Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 18/20 | 0.80 |
| ▸ | FNTB | P49356 | 18/20 | 0.80 |
| ▸ | SLC6A15 | Q9H2J7 | 3/20 | 0.67 |
| ▸ | PTAFR | P25105 | 1/20 | 0.58 |
| ▸ | HRH1 | P35367 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6179643 | 0.92 | FNTA (0.81) | FNTAFNTBSLC6A15 | |
| SCHEMBL6179026 | 0.89 | FNTA (1.00) | FNTAFNTBSLC6A15PTAFRHRH1 | |
| SCHEMBL6179842 | 0.89 | FNTA (0.75) | FNTAFNTBSLC6A15PTAFR | |
| SCHEMBL6176248 | 0.89 | FNTA (0.78) | FNTAFNTBSLC6A15 | |
| SCHEMBL6175425 | 0.87 | FNTA (0.73) | FNTAFNTBSLC6A15PTAFR | |
| SCHEMBL6179504 | 0.87 | FNTA (0.90) | FNTAFNTBSLC6A15 | |
| SCHEMBL6178141 | 0.87 | FNTA (0.72) | FNTAFNTBSLC6A15 | |
| SCHEMBL6180894 | 0.87 | FNTA (0.72) | FNTAFNTBSLC6A15 | |
| SCHEMBL7959419 | 0.85 | FNTA (0.69) | FNTAFNTBSLC6A15PTAFRHRH1 | |
| SCHEMBL7813174 | 0.84 | FNTA (1.00) | FNTAFNTBSLC6A15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1123931-B1 | Tricylic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | SCHERING CORP (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20020068742-A1 | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | BISHOP W ROBERT (US) | 2002-06-06 | — | — | US | disclosed |
| US-6365588-B1 | AS ANTINEOPLASTIC AGENT AND A POTENTIATING | SCHERING CORPORATION | 2002-04-02 | — | — | US | disclosed |
| EP-1123931-A1 | Tricylic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | SCHERING CORPORATION (US) | 2001-08-16 | — | — | EP | disclosed |
| US-6242458-B1 | INHIBITING FARNESYL PROTEIN TRANSFERASE IN A HUMAN | SCHERING CORPORATION | 2001-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068742-A1 | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | RASGRP1, CCNA1, CCNA2 | FNTA 516/4885FNTB 1222/4885SLC6A15 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.